

**Economic Assessment of Health Care: theory
and practice**

Jeff Richardson
Professor, Director,
Centre for Health Program Evaluation

August, 1990
ISSN 1038-9547
ISBN 1 875677 08 9

CENTRE PROFILE

The Centre for Health Program Evaluation (CHPE) is a research and teaching organisation established in 1990 to:

- undertake academic and applied research into health programs, health systems and current policy issues;
- develop appropriate evaluation methodologies; and
- promote the teaching of health economics and health program evaluation, in order to increase the supply of trained specialists and to improve the level of understanding in the health community.

The Centre comprises two independent research units, the Health Economics Unit (HEU) which is part of the Faculty of Business and Economics at Monash University, and the Program Evaluation Unit (PEU) which is part of the Department of General Practice and Public Health at The University of Melbourne. The two units undertake their own individual work programs as well as collaborative research and teaching activities.

PUBLICATIONS

The views expressed in Centre publications are those of the author(s) and do not necessarily reflect the views of the Centre or its sponsors. Readers of publications are encouraged to contact the author(s) with comments, criticisms and suggestions.

A list of the Centre's papers is provided inside the back cover. Further information and copies of the papers may be obtained by contacting:

The Co-ordinator
Centre for Health Program Evaluation
PO Box 477
West Heidelberg Vic 3081, Australia
Telephone + 61 3 9496 4433/4434 **Facsimile** + 61 3 9496 4424
E-mail CHPE@BusEco.monash.edu.au

ACKNOWLEDGMENTS

The National Centre for Health Program Evaluation is supported by a grant from the National health and Medical Research Council's Public Health Research and Development Committee, and by a matching grant from the Victorian Health Promotion Foundation. The research reported in this paper was made possible as a result of this support.

Contents

1. Introduction
2. The Departure from Welfare Theory
 - WTP versus an External Objective
 - The Ethical Basis of CUA
3. Cost Utility Analysis
 - The Measurement of Quality
 - Practical Issues
 - Theoretical Issues : The Unit of Measurement
4. Measuring Indirect Benefits in CUA
 - What to Include
 - Combining Direct and Indirect
5. Conclusions

References

List of Tables

1. Some utilities for health states
2. Measurement issues in CUA
3. Interviewing techniques
4. Theoretical issues in the measurement of utility and CUA
5. The choice of the cost-benefit ratio

1. Introduction

Health systems throughout the developed world have passed through two distinct phases and are presently entering the third. From the 1950s to the late 1970s virtually all of these countries experienced an increase in health expenditure so far in excess of GDP that the sectors share of the national product more than doubled. By the end of the period there was virtually unanimous agreement that expenditures were not being matched on the margin by improvements in health outcome. Following the economic downturn of the 1970s the second phase commenced. This was characterised by the greater restraint on health expenditures. For the OECD as a whole, health expenditure as a percentage of GDP rose from 3.8 to 7.0 between 1960 and 1980 but in the following seven years the increase was only 0.3 percentage points (Schieber and Poulter, 1989). By the middle of the 1980s concern was being expressed in a number of countries that indiscriminate fiscal measures were jeopardising the quality of the health service. Increasingly there has been a demand for resources within the health sector to be rationalised so that high priority areas may be separated from those where benefits are more problematical; that is, for resources to be allocated on the basis of costs and benefits. This has led to the belief that within the health sector the 1990s will be characterised as a period of economic evaluation.

While there can be little doubt that this would be a beneficial development, the techniques for the evaluation of health care have not fully evolved. This is partly a reflection of the imperfect state of evaluation techniques generally, but more particularly it is associated with problems that arise from the nature of the output. The benefits of health care include life and an improved quality of life. The measurement of these and their satisfactory integration with economic theory has not proved to be easy. The objective of the present paper is to outline the historical development of economic assessment in the health sector and, more importantly, to review a number of the unresolved issues. The review does not purport to be exhaustive and, in particular, it will emphasise two sets of issues which have received little attention in the literature namely, the value systems which underly the evaluation techniques and the measurement and inclusion of the "indirect" production benefits which result from the preservation of life.

The explicit evaluation of the costs and benefits of medical care becomes a particularly acute problem in health systems where services are provided by the Government or where their physical supply is directly or indirectly regulated. The absence of fully developed techniques for the achievement of this task may suggest the desirability of a free market approach to assessment. In this context it is worth noting that the exception to the general historical pattern described above has been the USA where the market based system has been perceived as being in a state of cost crisis since the 1950s. Phases have been characterised only by the intensity of the crisis. For

example, in the 1980s while other western countries constrained costs, the so-called "competition revolution" in the USA was associated with an acceleration in the rate at which health costs have been accelerating. It has been a combination of this US experience and a number of persuasive theoretical arguments that has led the majority of health economists and governments to doubt the efficacy of the market "solution". In the health sector this appears to be about as attractive as nature's solution to the problem of old age. Apart from its generally unacceptable distributional effects, the unregulated market does not appear to allocate health care resources efficiently. Market based systems may prove to be viable if an appropriate regulatory framework can be devised¹ but any system must face the apparently inescapable fact that consumers will not be the agents that decide between the technical alternatives (although the assessment may be based upon their preferences - see below). The agents making choices will, consequently, need an acceptable framework for measuring and comparing costs and benefits.

2. The Departure from Conventional Welfare Theory

Explicit project evaluation was a late arrival in economics². In its modern form it dates back to 1936 when a US law directed the army to investigate the costs and benefits of river and harbour projects for which there was no market. It took ten years for cost benefit analysis (CBA) to evolve into its present form. When compared with later forms of project evaluation, the defining characteristic of CBA is its attempt to reduce all benefits and costs to a single measurement unit, the dollar. While this has the major advantage of allowing a direct comparison of cost and benefits there has never been a satisfactory method for quantifying the value of life itself. Two quite different techniques were employed to measure this. First, and in the tradition of the material welfare school of Marshall and Pigou the human capital approach envisaged the value as "external" to the individual and to be measured by the individual's contribution to subsequent output. The approach was first used in the health sector by Mushkin (1962) and subsequently developed by Rice and Cooper (1967) and Cooper and Rice (1976). Because of its simplicity it has been the most commonly used measure in the cost benefit literature and was the method recommended by the US Public Health Service (Hodgson and Meiners, 1982). Two defects of the technique have proved to be fatal. First, it has strong and, to most, unacceptable distributional implications. Cooper and Brady (1976) for example, found the present value of a 25-29 year old male to be \$US475,000 for a white college graduate and \$US165,000 for a black high school dropout; a person approaching retirement aged

¹ See, for example, Enthoven, 1988 (and Scotton (1990)).

² For a review see Warner and Luce (1982).

65 had a present value of \$US41,000³. In all such studies women are valued less than men and the retired elderly have a present value of zero! Secondly, the dominant view amongst (non-health) economists has been that the appropriate measure of value is the intensity of individual preferences and that this is not reflected by future productivity.

The latter belief forms the theoretical basis for the alternative, willingness to pay (WTP), technique. Intensity of preference is believed to be reflected in the revealed expenditure of an individual. The problem of interpersonal comparison of welfare is resolved by appeal to the Kaldor-Hicks doctrine of potential Pareto improvement. In practice, a persons willingness to pay has been quantified using interviews, by extrapolation from the willingness to pay for an incremental improvement in safety and, most commonly, from the wage increments associated with hazardous jobs.

Like the human capital approach, willingness to pay can be criticised in both its application and on its theoretical foundations. In their review, Landefeld and Seskin (1982) note that, to date, the results obtained from the application of the technique have varied from the improbably high to the improbably low and, depending upon the results adopted, virtually any project could be accepted or rejected. As with the human capital approach, the technique has strong distributional implications that are likely to be widely rejected. The wealthy can reveal a higher value of life than the poor and the outcome of WTP based cost benefit analysis will favour this social group.

While the theoretical basis of WTP rests upon the widely accepted principles of welfare economics it is not clear that these are acceptable in the health sector. The value revealed by the measurement techniques described above is not the value of life per se but the value of the perceived *ex ante* risk. The compensation required to satisfy the potential Pareto criterion is similarly based upon the value of perceived risk. It is possible to infer the *individual's* value of life from the value of this risk only if the von Neumann-Morgernstern axioms (or an acceptable alternative set of axioms) are believed to describe individual behaviour. However there are now compelling theoretical and empirical reasons for rejecting these and with them the validity of the extrapolation from risk to the value of life⁴.

An alternative and more fundamental theoretical justification for the WTP technique is that revealed preference is the basis for valuation in welfare economics; that this cannot be revealed *ex post* (dead men may tell no lies but they also reveal very little!); that the value of a foregone life `ex post'

³ Quoted from Robinson, 1986.

⁴ For a theoretical and empirical review see Pope (1989) and Schoemaker (1982) respectively.

has little meaning and that, consequently, the appropriate magnitude to be measured is, in fact, the ex ante value of risk not the ex post value of a life⁵. In his original statement of this position Mishan (1971) concludes that despite its practical difficulties WTP is the preferred measurement technique because "there is more to be said for rough estimates of the precise concept than precise estimates of economically irrelevant concepts" (p.705). The statement reveals a surprising but widespread misunderstanding of the role of social values in economic evaluation. It may be true that revealed preference is the basis for evaluation in welfare economics generally. The relevant issue, however, is whether or not it *should be* the basis in the health sector. While there has been a strong liberal tradition in economics and western society in which individuals are responsible for both choices and consequences there has also been a more paternalistic tradition which imposes choices when the consequences of consumer sovereignty are deemed to be undesirable. While no fully consistent and theoretically satisfying method has been devised for determining when there should be interference with individual choice, there is no doubt about either the existence of such a social value system or the ability of society to distinguish between different choice contexts. Historically one of the clearest examples of such a social objective has been the minimisation of *ex post* mortality and morbidity⁶. There has been little public concern with ex ante risks per se. This implies that, to the extent that CBA is specifically designed to assist with *social* decision making, the ex ante concept referred to by Mishan and other defenders of conventional welfare economics is an inappropriate basis for measurement. In Robinson's terms:

"It is clear that the subjective orientation of the willingness to pay approach could lead to an allocation of public funds in a manner inconsistent with the principles of cost effectiveness. These principles maintain first and foremost that governmental energies should be devoted to those areas where the potential improvements in health status and longevity are greatest. There is no reason to assume that the most cost effective programs, where benefits are measured in terms of mortality and morbidity statistics, would, in every case, be those most appreciated by the citizenry. Indeed, it is precisely in impatience with the allocation of public funds according to the subjective preferences of the politically powerful sectors of the population, rather than according to objectively measurable standards of

⁵ For an interesting debate on this issue see the exchange between Broome (1978, 1979) and Buchanan and Faith (1979) Leigh-Jones (1979) and Williams (1979).

⁶ The social concern is neither surprising nor inconsistent with the emphasis on freedom of choice elsewhere. In most choice contexts the consequences of ex post "wrong" decisions are not catastrophic and error learning is possible. Error learning is seriously inhibited by death.

maximum effectiveness, that lies at the root of economists interest in cost benefit and cost effectiveness analysis."

Robinson, 1986 (p.148)

In practical terms, the consequence of using these techniques for the measurement of human life was a widespread perception that CBA was not a very useful technique to assist with the allocation of health care resources (see for example Abel Smith, 1985). The next methodological development occurred in the 1950s. It reflected a more general recognition of the fact that in a number of areas, and not simply health care, program benefits could not sensibly be converted into dollars. Once again it was the US military that took the initiative. With the development of cost effectiveness analysis (CEA) projects were ranked according to the criterion of cost per unit of effectiveness. For the military, projects would be preferred which had, for example, a lower cost per death inflicted (on the enemy!) or in "macro" analysis, cost per mega-death. As noted, similar problems of evaluation arise in the health sector and the techniques developed by the military were adapted - with, of course, some modification to the unit of effectiveness. In health evaluation this has sometimes been measured by the number of morbid days or episodes of illness. On occasions, an intermediate measure has been used such as the number of cases of a disease detected by a diagnostic test. Most commonly, however, output has been equated with the number of life years saved. Thus a redistribution of funds to projects with a low cost per life year will increase the total number of life years that may be saved.⁷

The major weakness of CEA is that it treats all life years as having equal value no matter what the quality of the life. The alternative interventions being analysed may have different side effects and a longer life may, rationally, be traded off against comfort and functional ability. Both CBA and CEA refer to these quality of life factors as "intangibles", to be noted but not quantified. With the development of cost utility analysis, (CUA) in the last twenty years, techniques have evolved which permit the quantification of these intangibles and their inclusion in the analysis by the calculation and comparison of costs per Quality Adjusted Life Year.

⁷ The major CEA studies in the literature are reviewed by Drummond (1981).

3. Cost Utility Analysis

The Measurement of Quality⁸

It has been recognised for a long time that evaluation studies should include the measurement of the quality of life and a very large number of health status measures have been developed.⁹ However, the usefulness of these instruments has been variable. Many have had poor if any evidence of validity or reliability and the purpose for which they were developed has varied. While many of the instruments may have contributed in a general sense to the "evaluation of health outcome" they have often been unsuited to the specific question addressed in economic evaluation, namely, whether or not they indicate a treatment which should be chosen in preference to some other treatment for the same or for some other disease.

The latter question is explicitly addressed by cost utility analysis (CUA). Projects or options are ordered according to the cost per Quality Adjusted Life Year (QALY) attributable to the project. All else equal, the most desirable options are taken to be those which result in the cheapest QALYS. That is, QALYS are the criterion of value in the sense that more are better and, all else equal, projects with more QALYS should be preferred. Despite the recognition of numerous practical problems there appears to be a fairly widespread acceptance of the steps involved in the calculation of QALYS. They are estimated as expected life years times an index of "utility", where this is measured on a 0-1 scale and is taken as quantifying that aspect of the quality of life upon which decisions should be made.¹⁰

Five techniques have been used which purport to measure utility directly. These involve the use of category rating or a rating scale (RS), the standard gamble (SG), the time trade off (TTO), equivalence techniques (ET) and magnitude estimation (ME). (For a detailed description of each of these see Torrance 1986). Each technique involves the presentation of a health state description to interviewees and the eliciting of their preferences for the health state relative to some reference

⁸ The most comprehensive statement on utility measurement is Torrance (1986).

⁹ Some of the most well known are the Sickness Impact Profile (SIP) (Bergner et al 1976), the Spitzer QL index (Spitzer et al 1981), the Quality of Wellbeing (Kaplan et al 1976) and the Nottingham Health Profile (Hunt et al 1986). For review of the major scales see McDowell and Newell (1987).

¹⁰ For a discussion of these steps see Gudex and Kind (1988).

states, usually full health and death. The scale is calibrated by setting the value of these reference states equal to unity and zero respectively. The utility revealed by these techniques is taken as having an interval property. Thus, for example, the difference between utility values of 0.2 and 0.4 is treated as being quantitatively equivalent to the difference between 0.6 and 0.8. The property is required for the valid summation of utilities.

A second, indirect, approach to measurement requires the prior establishment of a "multi attribute" utility (MAU) scale which may be applied to any health state. Three commonly used scales have been devised by Rosser and Kind (1978), Torrance (1982) and Kaplan et al (1976, 1982). With each of these, a health state is broken down into different "attributes" or "dimensions" such as "physical functioning", "socio emotional function" and "health problem". Each attribute has a separate scale with scores initially determined from interviews using one of the techniques listed above. A particular health state may then be measured and scored on each scale and the scores combined with a predetermined formula.

Using both the multi attribute and the holistic approach to measurement a large number of health states have been assessed and "league tables" published showing the utility of different states (see table 1). It is commonly accepted that "CUA can no longer be considered as being in the experimental stage but is now at the point where it merits serious consideration by health care decision makers" (Drummond, 1987). At least one regional authority in the UK has explicitly employed it as an aid to decision making (Gudex, 1986).

Practical Issues

While not necessarily disagreeing with the conclusion above, it should be recognised that there are still a number of very fundamental conceptual and practical questions which are unresolved. Tables 2-4 lists the chief issues noted in the literature and classifies them (sometimes a little arbitrarily) as dealing with measurement, interview technique or theory.

The first of these groups of issues is summarised in Table 2. A basic requirements of measurement is that it should be valid (measure what it purports to measure), internally reliable (repeated measurements should produce the same result) and have an acceptable level of precision (standard deviation of individual measurements). These are empirical issues and there has been little such developmental research reported in the literature. Validity must be established by a comparison of results against a gold standard. The conventional - but not unanimous - view is that this is provided by the standard gamble, the technique derived from the von Neumann-

Morgernstern axioms of consumer choice. However most of the techniques have not been validated against this yardstick. In some instances other approaches to validation

TABLE 1 SOME UTILITIES FOR HEALTH STATES

Health State	Utility
Healthy (reference state)	1.00
Life with menopausal symptoms (judgment)	0.99
Side effects of hypertension treatment (judgment)	0.95-0.99
Mild angina (judgment)	0.90
Kidney transplant (TTO, Hamilton, patients with transplants)	0.84
Moderate angina (judgment)	0.70
Some physical and role limitation with occasional pain (TTO)	0.67
Hospital dialysis (TTO, Hamilton, dialysis patients)	0.59
Hospital dialysis (TTO, St John's, dialysis patients)	0.57
Hospital dialysis (TTO, general public)	0.56
Severe angina (judgment)	0.50
Anxious/depressed and lonely much of the time (TTO)	0.45
Being blind or deaf or dumb (TTO)	0.39
Hospital confinement (TTO)	0.33
Mechanical aids to walk and learning disabled (TTO)	0.31
Dead (reference state)	0.00
Quadriplegic, blind and depressed (TTO)	<0.00
Confined to bed with severe pain (ratio)	<0.00
Unconscious (ratio)	<0.00

Source: Torrance (1987).

have been used. The rating scale and magnitude estimation techniques are derived from the psychometric literature and proponents point to this in support of the procedures. Few studies have been undertaken to determine internal reliability. While the existing results appear "fairly satisfactory" (Torrance, 1986) they do not represent a very secure basis for a new branch of health measurement.

A second and related issue to these questions is whether or not measurement techniques produce the same result. If so, then confidence in each is increased as it would support the view that they are measuring a common quantity. Once again, however, evidence is scarce. A reasonable correspondence has been found between the time trade-off and standard gamble. While Richardson et al (1990) also find a close correlation between these, they were also able to reject the hypothesis that the two measures, or the rating scale gave the same result for the health state being measured. In the same study it was found that the two multi attribute scales investigated seriously underestimated utility - a result predicted by the authors as the health state - breast cancer - involves significant psycho-social costs and these are not adequately measured in the two MAU scales. A reasonable inference from this latter result is that, while quicker and cheaper to use, the all purpose MAU scale is likely to give a less accurate result than the health state specific vignette approach to measurement. Finally, Torrance (1976) has suggested that power function transformations may improve the relationship between the Rating Scale and Time Trade Off. The function reported by Torrance could not be reproduced by Richardson, et al (1990) and it did not improve the correlation between the results of the RS and TTO.

An important measurement issue which has received some recent attention is whether or not a single index of utility is applicable to a health state over a period of time. QALYS are calculated by multiplying life years by an index of utility. The question is whether or not the value of the index varies with the stage of a person's life and with medical prognosis. More generally, the functional relationship between a person's utility and time may be incompatible with a single yearly index. An additional problem is that future benefits - QALYS - are normally discounted in CUA studies in an orderly, exponential, way using an estimate of the social rate of time preference. However, individuals may not behave in this way when evaluating future benefits.

Health states are unlikely to remain unchanged until death. The usual approach to this problem is to evaluate each of the health states which will be encountered and then to sum the discounted QALYS experienced in each health state on the assumption that the health states are independent. If the assumptions discussed above are invalid then this procedure is also invalid. Mehrez and Gafni (1989a) have suggested that, for this reason, the usual composite approach to the calculation of QALYS should be replaced by a holistic measure of the utility of an entire multi-period scenario. They suggest that the resultant utility be converted into Healthy Year Equivalent (HYE's). The suggested change in title - HYE to replace QALY - would emphasise the new methodological basis for the calculation. Richardson, et al (1989) have investigated this issue empirically. They found that the holistic and composite approaches to a multi-state scenario give very different results, thereby supporting Mehrez and Gafni's suggestion.

TABLE 2 MEASUREMENT ISSUES IN CUA

Issue	Authors	Comments
1. Are utility measures reliable?	Torrance, 1976, 1982 Churchill, 1984 Buxton, 1988 Richardson et al, 1990a	Internal, test and re-test reliability "satisfactory". However correlation between tests is not high.
2. Are utility measures valid?	Torrance, 1986 Churchill et al, 1984, 1985 Evans, 1985, 1987	Validity is often defined using the SG as the gold standard. See Section 4.
3. Do different utility measures give the same result?	Torrance et al, 1976 Read et al, 1984 Buxton et al, 1986 Richardson et al, 1990	Patient and clinician's evaluations correspond. Comparison suggests: TTO < SG. RS systematically differs. Orders of magnitude of TTO, and SG very similar, but statistically significant differences exist.
4. Do MAU measures give the same results as direct measurement?	Buxton et al, 1986 Richardson et al, 1990	Rosser scale must be transformed. Similar order of magnitude of results. Present MAU scales appear unable to measure disutility of psycho-social distress. No comparisons of QWB and MAU scales.
5. Can results from one scale be transformed to obtain results compatible with another?	Torrance, 1976 Richardson et al, 1990	Torrance improves compatibility of RS and TTO using a power function. Richardson et al cannot replicate result.
6. Can utility results be applied to individuals or only to populations?	Loomes & McKenzie, 1989 Torrance & Feeny, 1989	Standard deviation of individual measures is high. For the mean value of populations it is not.
7. Will utility vary with SES?	Sackett & Torrance, 1978	This single study found only a weak relationship.
8. Is the utility of a health state constant through time?	Sackett & Torrance, 1978 Mehrez & Gafni, 1989 Loomes & McKenzie, 1989 Richardson et al, 1990	Daily utility falls with duration of condition. Utility may vary with prognosis, stage of life, idiosyncratic time preferences. Rate may differ when future generations' welfare is affected. Suggests the need to measure an entire health scenario until death or return of full health, not an annual index of health state utility.

As reported in Table 3 there has been a fairly substantial investigation of the importance of the interview. This draws upon an extensive literature on the subject outside the context of CUA. As elsewhere, it has been found that results are sensitive to the way in which health states are described and the way in which scales are presented. Two additional questions are relevant. The first is the choice of subject for interview. Some have argued for the use of patients or health professionals who have experienced or observed the health state and can appreciate and evaluate it more accurately. Others have argued that a random cross-section of the society should be interviewed as it is society's resources that are allocated to health programs. A further view is that if CUA is to reflect consumer sovereignty, interviewees should be potential patients as it is the values of this group that would be relevant if individual decision making was possible. The second question is whether stated preferences in the context of an interview correspond with the

preferences individuals reveal when faced with a real choice. There has been no evaluation of this difficult issue in the CUA literature. However, results from transport economics suggests that "stated preferences" closely correspond to "revealed preferences" when interviewing is carried out in an appropriate way.

Theoretical Issues

The theoretical issues discussed in the literature are summarised in Table 4. Only three of these will be considered below. The first returns to the question of the unit of measurement and the value basis of CUA. The second discussed in section 4 reconsiders an old issue in the CBA literature namely, whether or not the "indirect" production benefits resulting from averted death should be included using the gross value of production or the value net of consumption. Thirdly, there is a consideration of how these "gross or net" benefits should be included in the analysis.

The Unit of Measurement

In Section 2 of the paper it was noted there have been two traditions in economics reflecting two sets of social values. In the first (material welfare) tradition value is "external"; in the second, which commenced with Robbins, a value is internal. It is equated with the strength of an individual's preferences and normally revealed through the individual's willingness to pay.

Cost utility analysis represents an interesting fusion of the two traditions. On the one hand, the QALY is directly related to an external measure - the life year - and one which combines both dimensions of public policy, namely, morbidity and mortality. On the other hand, the evaluation of healthy year equivalents is based upon individual preferences. The issue which has not been resolved in the literature is which of the available measurement techniques reflects, most accurately, the intensity of an individual's preferences. Most of the theoretical discussion in this respect has been concerned with the adequacy of the von Neumann-Morgenstern axioms and whether the standard gamble is, therefore, a satisfactory gold standard for measurement. The theoretical issue is whether or not the axioms allow for the "specific utility of risk" - something which von Neumann and Morgenstern did not claim for the axioms (and explicitly disclaimed) but which subsequent writers accepted. There has now been a significant body of empirical research to determine whether the axioms are supported by observed behaviour. As noted earlier in the paper the outcome of this debate is that the axioms cannot be accepted as generally true in all contexts and that, consequently, the standard gamble cannot be accepted as a gold standard for measurement.

Both the standard gamble and the measurement techniques observed from the psychometric literature have a common feature. The measurement requires information on two separate relationships. The first is between the health state described to individuals and the scale used by the technique (centimetres on the rating scale; probabilities with the standard gamble); the second is between the scale and the intensity of individual choice. In each of these cases the second relationship is unknown. In the psychometrics

literature it is simply assumed that there is a one to one relationship between the scale and preferences and that the scale has an acceptable interval property. As there is no linear relationship between the different results

TABLE 3 INTERVIEWING TECHNIQUES

Issue	Authors	Comments
1. Who should be interviewed? . patients . cross section of population . health professionals	Torrance, 1986 Loomes & McKenzie, 1989 Epstein et al, 1989 Carr-Hill, 1989	Patients often give higher utilities than non patients for a given health state. Claimed that patients and professionals have a greater understanding of the health state The counterclaim is that societal values including those (i.e. of non patients) are desired, not those of patients.
2. Are patient responses the same as non patients?	Epstein et al 1989	High correlation for overall health, functional, social and emotional status.
3. How adequate are health	Boyd et al, 1982 Llewellyn Thomas et al, 1984 Torrance, 1986 Carr-Hill, 1989	General agreement that state descriptions? good descriptions are a critical factor in accurate measurement but level of detail in practice varies greatly. Sequence and method of presenting descriptions alters results.
4. Do utilities depend upon the 'context' of the health state?	Brooks, 1988 Hellinger, 1989 Sutherland et al, 1983	Results differ significantly with context which casts doubt upon conventional theory.
5. Will utilities vary with the reference points used for a scale?	Hershey et al, 1982 Sutherland et al, 1983 Llewellyn Thomas et al 1982	Yes
6. Are utilities sensitive to 'framing' of descriptions and labels?	Brooks, 1988 Hershey et al, 1982, 1985 Sutherland et al, 1983 O'Connor et al, 1987 Wilson et al, 1987 Sackett & Torrance, 1978	Outcomes normally found the to vary with 'framing' and use of labels. O'Connor found no 'framing' effect. 'Positive' language increases utility values.
7. Will stated preference (in an interview) correspond with revealed preferences?	Brooks, 1988 Carr-Hill, 1989	No reliable results but those from transport economics supports the validity of stated preferences, correctly obtained.

TABLE 4 THEORETICAL ISSUES IN THE MEASUREMENT OF UTILITY AND CUA

Issue	Authors	Comments
1. Is the theoretical basis of the SG acceptable: Is it a 'gold standard'?	Torrance & Feeny 1989 Schoemaker, 1982 Hershey et al, 1982	See section 4 of this paper. The Von Neuman-Morgenstern axioms are often contradicted. The axioms have been defended as being normative, not positive.
2. Does SG produce consistent results?	Hershey et al, 1985 Llewellyn Thomas et al 1982	Achieving equivalence in the SG by varying probabilities gives a different result from varying certainty quantities. Results depend upon outcome.
3. What is the theoretical basis of the TTO technique?	Torrance, 1986 Mehrez & Gafni, 1989b	Initially proposed as an approximation to the SG revealing 'value' not 'utility'. M&G argue that the TTO identifies points on an indifference curve between quality and quantity.
4. Should only the patients utility be considered?	Loomes & McKenzie, 1989 Carr-Hill, 1989	L&M argue that a wider group, namely those chiefly affected, should be included.
5. Should health costs of a normal life be considered as one of the costs of saving a life?	Weinstein & Stason, 1976	In principle, yes; in practice this may not make a great difference.
6. How should medical risk and uncertainty be included?	Gafni & Torrance, 1984 Mehrez & Gafni, 1989b Hellinger, 1989	M&G argue that this necessitates the use of the SG. G&T argue risk is the sum of gambling, quantity and time preference effects. H's empirical results suggest no pure risk behaviour but context specific behaviour.
7. Is total cost/QALY the appropriate ratio for choice?	Linard, 1990 Birch & Donaldson, 1987	Numerator should have budgetary costs only if budgets are limited. Indirect benefits cannot therefore be in the denominator: they cannot be combined with QALYS in the denominator. Decisions should refer to marginal changes where possible.
8. Is it possible to aggregate utility across individuals?	Torrance & Feeny, 1989 Torrance, 1986 Carr-Hill, 1989	Generally agreed this must be and is done in practice. Limited enquiry into the assumptions which permit this and little discussion of the relation between assumptions and underlying value systems.
9. How should QALYS be distributed?	Kuhse & Singer, 1988 Richardson & Hall, 1990 Loomes & McKenzie, 1989 Wright, 1986	QALYS may be valued differently at different ages or subject to some other distributional criteria
10. Which discount rate should be applied for future values?	Torrance & Feeny, 1989 Richardson et al, 1990 Evans, 1990 Lipscombe, 1989 Carr-Hill, 1989	Dispute between the use of the social opportunity cost and the social rate of time preference.

produced by the different psychometric scales this latter conclusion must be wrong. In the case of the standard gamble the second relationship is confounded by the specific utility of risk.

For this reason, Richardson (1990) has tentatively suggested that the preferred measurement technique should be the time trade-off. With this, individuals indicate directly the number of healthy years which are considered to be equivalent to a given number of years in the health state being evaluated. Preferences are directly measured by the healthy year equivalents without the need for a confounding, intermediate, scale. The healthy year equivalent (HYE) revealed by subjects is the unit of output.

The principle ethical question to be resolved in cost utility analysis is the way in which individual evaluations should be aggregated and, therefore, the way in which interpersonal comparisons are to be made. As noted by Torrance (1986) the basic assumption made is that "the difference in utility between being dead and being healthy is set equal across people. In this way the method is egalitarian ... each individuals health is counted equally (p.17). As a result the QALYs or HYEs gained by different individuals may simply be summed. In Mooney's (1989) phrase this implies a form of "quasi utilitarianism" in which the maximand is not total utility but a weighted average of individuals utilities where the weights are designed to treat individuals equally irrespective of the absolute intensity of their preferences.

Such quasi utilitarianism necessarily conflicts with other ethical bases. Libertarians would reject an aggregation rule which constrained an individual's right to reveal their own preferences, that is, through their willingness to pay. More generally, those subscribing to a deontological view of ethics would argue that resource allocation should be determined, not only by consequences but by "ethical rules" and "human rights". Thus, for example, in his critique of QALYs Harris (1987) argues that the only priority in health care should be the preservation of life and that all have an equal right to life no matter what its length or quality. In his critique of this paper Williams (1987) notes the incompatibility of the ethical bases and simply argues that "at the end of the day we simply have to stand up and be counted as to which set of principles we wish to have underpin the way the health care system works" (p.123). Proponents of CUA must commence with the view that there will be widespread acceptance of the ethical principle that, all else equal, more healthy year equivalents should be preferred to less.

4. Indirect Benefits

What to include

The direct effect of a successful medical intervention may be an increased number of life years or QALYS. However, if the beneficiaries are in the workforce there will also be an increase in the value of future production. This has been treated two ways in the literature. In some UK studies it has been ignored, the argument being that the purpose of the UK National Health Scheme is to maximise health and that it is not concerned with other objectives (see Williams (1985)). While resolving very decisively the issues raised below this is certainly an anomalous position for an economic analysis to adopt. As Klarman (1965) notes in his discussion of the issue "there is a distinction between a health program that saves people from death for useful labour and one that saves people from death to pursue an unproductive life". (p.380) The more common approach has been to subtract the present value of indirect production benefits from the direct cost of the procedure to obtain a net resource cost per QALY.

At the end of the 1960's there was some discussion of whether or not the appropriate quantity to be included in an economic evaluation was the full value of production or the value net of consumption. In the words of Prest and Turvey (1965)¹¹ "if society loses the production of the decedent, does it not also gain by not having to supply his own consumption" (p.722-723).

The answer given to this question depended upon the viewpoint explicitly or implicitly adopted on the composition of "society". Dowie (1970) notes that it is the "slipshod use of "society", "community", "nation" [that] is responsible for the bulk of the confusion in the health literature" (p.27). He quotes approvingly Weisbrod's resolution of the issue.

"The choice between the two measures of the economic value of a person - present value of gross or net future earnings - rests upon the viewpoint taken ... If "society" is defined to include everyone, including the individual whose value is being considered, then his contribution to the group is the total value of his output, and his "value" is the present value of his *gross* future earnings. But if "society" is so defined as to exclude the individual whose life is being valued (for example, as all those who would be left were he to die), then his contribution to "society"

¹¹ **Quoted from Dowie (1970). Also see Dowie for a review of this debate.**

consists only of any excess of what he adds to total output over what he subtracts from it, his consumption; and his economic worth is the present value of his *net* future earnings". (p.35-36)

Others did not adopt such a neutral position as Weisbrod. Mishan (1971), for example, simply asserts that the net production method "is not satisfactory for the simple reason that it has no regard for the feelings of the potential decedents. It restricts itself to the interest only of the surviving members of society: it ignores society *ex ante* and concentrates wholly on society *ex post*" (p.690). There are, as Dowie (1970) notes a large number of potential social groupings whose members' feelings may or may not be included. A more persuasive argument for the *ex ante* definition of society is provided by Prest and Turvey:

"... the society whose representatives decide whether or not to undertake a measure which would save lives includes those people who may lose their life if the proposed measure is not undertaken. Hence, so the argument might run, society is relevantly defined as including the prospective decedent and his consumption is part of the social loss contingent upon his death" (p.723 quoted from Dowie (1970)).

These arguments appear to have been decisive and the overwhelming majority of the evaluation and cost of illness studies in the health economics literature have used the gross value of production as the preferred measure of material benefits. The arrival of CEA and CUA alters the logic of the previous arguments. However this does not appear to have been recognised in the literature and the "material benefits" of a person's life continue to be included using the gross measure. Previously, and in the tradition of the material welfare school, the value of life was being equated with a value of the consumption benefits. Some of these were enjoyed by the individual producing the income (measured consumption) and some were enjoyed by unidentified persons who were the beneficiaries of the individual's savings and tax payments. Both CEA and CUA *replaced* this method of valuing life with an analysis in which the life year or QALY was itself the unit of output. From biological necessity a life year must involve some consumption and there is probably little doubt that respondents to a CUA interview presume that the different health scenarios presented to them for assessment do not involve a reduction in their material standard of living. This implies that the inclusion of life years as a benefit and future consumption as a negative cost involves double counting of these benefits.

Despite the *prima facie* appearance of double counting, the gross measure of output might be defended on the grounds that for "conceptual clarity" material benefits should be separated from the non-material benefits of a life *per se*. The former may be precisely quantified whereas the latter involves ethical and emotional issues that confound measurement. Following this line of argument,

the life year does not measure the intensity of the material benefits experienced so that these may be separately measured. Even if it is the individual gaining the life years who also receives the consumption benefits this is an issue of distribution, not production and, in principle, could be subjected to the potential compensation principle.

The argument is not compelling. Even accepting the ex ante view of society and the concept of a life year uncoupled in some sense from material benefits (and it is not obvious that such an uncoupling results in "conceptual clarity") a closer examination of the distributional consequences of the argument is likely to result in its widespread rejection. Suppose that two individuals, A and B consume all of their income, C_A , C_B and these individuals require interventions which would result in a same number of additional life years for each. According to the previous argument, priority would be determined by comparing the "net resource cost" ($T_i - C_i$) where T and C represent the treatment cost and individual's consumption respectively. The two individuals would be equally likely to receive the treatment when $T_A - C_A = T_B - C_B$. By assumption, neither A nor B contributes to the collective provision of health care and, consequently, T_A and T_B represent the amount the remainder of the society is prepared to pay for the person's treatment. The equation indicates that the higher the value of consumption the higher is the value of T that the society is prepared to pay. In general, this rule requires non recipients of the benefits to pay more, and implicitly value more highly, an individual when that individual consumes more. While conceivable, this situation appears to be an improbable description of social values and precisely the situation that the introduction of CEA and CUA was intended to avoid. The rhetoric and provision of health care in most national health schemes is more compatible with the view that the willingness to pay by non recipients is determined by the presumed impact on life and the quality of life, that is, by the units adopted directly in CUA. This implies that the relevant benefits are fully included in the measurement of QALYs and that a further adjustment for consumption will indeed lead to double counting.

The assumption in the previous example that consumption is equal to the full value of income is not generally true. Normally the present value of an individual's consumption is less than the present value of income because of taxation and savings the cumulative value of which is passed on as an inheritance to children and other heirs. For the recipient of state funded pensions this situation might be reversed and the value of consumption could exceed the value of an individual's earned income. Consequently there are a number of alternative "net resource costs" associated with an intervention. Using the notation: T = direct treatment costs; Y = earned income; C = consumption; X = tax; S = savings; P = pensions; and where all the values represent the cumulative lifelong present value of the magnitudes these are:

- (i) $(T - Y)$: This is the usual measure discussed above. It implies a higher willingness to pay by the rest of society as a person's own consumption rises.
- (ii) $(T - (Y - C)) = T - (S + X)$: This is the net measure also discussed above. It assumes a greater willingness to pay as the individual contributes more to the society via taxation. It also assumes a greater willingness to pay as the individual accumulates greater wealth for his or her heirs.
- (iii) $T - (Y - C - S) = T - X$: Treatment costs net of tax excludes the benefits received by heirs and assumes that the willingness to pay of society rises with a person's contribution to the general social wealth,.
- (iv) $T + P$: This is the special case of (ii) in which $Y = 0$ and $C = P$. For consistency, if the general contribution of individual's to the society via taxation is considered relevant to the resource cost then a negative contribution via pension payments may also be considered relevant.

The four options do not indicate a different concept of cost per se but rather a different view of the social groups whose benefits should be included in the analysis. The need to specify this arises both from the fact that in CEA and CUA the benefits to an individual of extending their life are measured separately from other material benefits and from the fact that the distributional affects of these benefits are very precisely focused. The argument here may be summarised by saying that under these circumstances the cost benefit question should not be posed in terms of abstract "net social costs" since, as Dowie notes, the term "society" is too hazy. Rather it should specify the group which bears the costs and the group whose material benefits are considered to be relevant. The latter decision is unavoidably value laden. The fourth measure above makes this most obvious. All else equal the inclusion of pensions as a cost to the remainder of society will reduce the likelihood of their provision. It is, however, an inescapable fact that pensions involve a cost to the remainder of society. There is, of course, no correct measure as the choice between these options depends upon distributional judgments. As noted earlier, some English writers disregard all indirect benefits. It seems likely, however, that most would wish to include at least the value of positive tax payments in the analysis. The treatment of savings and pensions is more problematical.

Combining Direct and Indirect Benefits

Following a decision about the appropriate definition of material benefits there remains the question of how these should be combined with other relevant information on costs and benefits in order to evaluate a project. With the notable exception of Linard (1990) the complexities of this task do not appear to have been fully appreciated in the health literature. A prior issue that needs resolution

concerns the purpose of project evaluation. One view is that this is simply the determination of the actual projects to be undertaken by an authority or enterprise. From this perspective the usual interpretation of evaluation criterion is often incorrect or misleading. Linard (1990), for example, argues that:

"an evaluation of an isolated proposal which reports that "... benefits are greater than costs therefore the project is worthwhile ...", or that "... benefit/cost ratio is greater than 1.0 therefore the project is worthwhile ...", is implicitly assuming that unlimited resources are available, that there are no budget constraints. Using Mishan's terminology, such studies are "*economically irrelevant*". Worse, they are misleading to the public and the decision makers".

From this perspective "the benefit/cost ratio is a misnomer; (society's benefit - society's cost/net budgetary costs ratio would be more accurate" (Keeler and Cretin (1987)).

These latter authors, however, disagree with the narrow interpretation of the objective of CBA. They argue that:

"In the health field, cost-benefit and cost effectiveness analysis have been carried out for two purposes. The first and more frequent application found in the literature uses cost-benefit or cost effectiveness analysis as a tool to describe and evaluate new and promising health care programs. ... the goal is to improve the policy debate rather than to specify the correct policy. The second, less frequently reported use addresses the problem of how an agency with a fixed budget should spend its funds to maximise net social benefit" (p.276).

A second prior issue is the choice of an evaluation criterion. Of the various decision rules three are relevant here. These are based upon the net present value (NPV), the benefit to cost ratio and the net cost per unit of output. The first provides the normal gold standard for evaluation; the second is often accepted as indicating the rank order in which projects should be conducted and the third is the criterion used in CEA/CUA.

Projects will not always appear to be ranked the same way with these three criteria. This is illustrated in Table 5 using three projects P_1 , P_2 and P_3 . The value of a QALY is assumed to equal \$100.00 (this is arguably a little low!!). Other benefits (OB) arise from the value of future (net or gross) production by the individual receiving treatment. Treatment costs, T, are the direct cost of gaining the additional QALYS.

The apparent anomaly shown in Table 5 arises from the interpretation of the three criteria as being appropriate for the ranking of projects. Strictly, they are not. In the absence of a budget constraint the NPV criterion is that a project should (not) be undertaken when the NPV is positive (negative). With the other two approaches projects should be undertaken when the ratio exceeds unity. The approaches are consistent in determining this issue. If the NPV is positive, both ratios will exceed unity.¹² If projects must be ranked, then additional information is required on the scarce factor - usually a budget constraint - which prevents all projects being undertaken for which ratios exceed unity and the NPV is positive.

As CEA/CUA cannot use the NPV criterion one of three ratios must be selected. Their usefulness in the presence or absence of a budget constraint is summarised in Table 6. In the latter context the purpose of the ratio, as noted by Keeler and Cretin, is to improve the policy debate with respect to particular programs. Results may be used to promote particular techniques or to highlight irrationalities in the existing allocation of resources. To achieve this

¹² If NPV = Q + OB - T > 0
 T < Q + OB
 R1 = T / (Q + OB) < 1
 (T - OB) < Q
 R2 = (T - OB) / Q < 1

TABLE 5 PROJECT EVALUATION USING THREE CRITERIA

	Project			Ranking (No Budget)
	P1	P2 (=2 * P1)	P3	
<u>Data</u>				
QALYs (Q)	1.0	2.0	2.0	
← Dollar value of Q	100	200	200	
Other Benefits (OB)	60	120	0	
Cost (T)	100	200	100	
<u>Criteria</u>				
NPV (gold standard)	60	120	100	$P_2 > P_3 > P_1$
$R1 = T/(Q + OB)$.625	.625	.5	$P_3 > P_2 = P_1$
$R2 = (T-OB)/Q$.4	.4	.5	$P_1 = P_2 > P_3$

objective the meaning of the ratio must be clear and persuasive. The ratio of the net cost to life year or QALY has this property. The unit of output is comprehensible as is the "net resource cost". For a given project scale, as defined by the life years or QALYS gained, the ratio will maximise net present value and this is independent of the valuation of life years.¹³ By contrast with this clarity, the cost to benefit ratio or cost to net benefit ratio is difficult to interpret. The combination of life years and other benefits requires that one of these magnitudes be converted into the units of the other and, as noted, the purpose of CBA/CUA was to avoid such a conversion. If life years were changed into dollar equivalents to allow the calculation of a cost-benefit ratio, debate and opposition would inevitably focus upon the method of conversion.

Project selection in the context of a fixed budget should not be based upon a net cost ratio as this will not maximise either life years or the NPV for a given expenditure. This self evident result follows from the fact that the budget may be quickly exhausted upon projects with a large budgetary, but low net, cost. In this context only the budgetary costs should be in the denominator as this will indicate where the greatest benefit is achieved per unit of the constrained resource. As net and not gross benefits should be maximised the conventional (gross) cost-benefit ratio is also of no use in this context.

In principle, the net benefit to budgetary cost ratio will indicate the order in which projects should be implemented to maximise net social benefits from a fixed budget. In practice, and as noted earlier, the approach cannot be used in a theoretically satisfactory manner. This is the major conclusion of Linard (1990) who notes that:

"In a situation of sectoral budget constraints the non-budget "dollars" should be aggregated with the effectiveness or utility "benefits" for comparison with the budget outlay. This, of course, destroys the simplicity of the ratio, creating major problems for comparison or interpretation. However having a "simple" ratio is of no benefit if it is irrelevant to the objective function". (p.12)

At this stage the dilemma would appear to be intractable and only *ad hoc* solutions appear to be tenable. For example, making the heroic assumption that investment within an agency is based upon rational planning, the value of life within that agency could be set equal to the maximum expenditure currently undertaken to save the life of

¹³ Suppose $(C_1 - OB_1)/Q_1 < (C_2 - OB_2)/Q_2$
 if $Q_1 = Q_2 = Q$
 $Q + OB_1 - C_1 > Q + OB_2 - C_2$
 $NPV_1 > NPV_2$

a person plus the estimated value of the indirect benefits. This would provide a minimum estimate of the value of life for investment purposes within that agency.¹⁴ If the assumption of rational planning in this context is too fanciful - and to many it appears like oxymoron - then an arbitrary figure could be selected for planning purposes, possibly based upon observed willingness to pay elsewhere. The adoption of such a heuristic would not be equivalent to a reversion to a pre CEA/CUA methodology. The importance of the estimate would be limited by the relative importance of

TABLE 6 THE CHOICE OF THE COST-BENEFIT RATIO

Ratio	Fixed Budget	No Constraint
$C - OB)/Q$	INVALID: Does not maximise QALYS	Correct ranking to produce life years most efficiently
$C/(Q + OB)$	Maximises benefits but unmeasurable	No clear interpretation
$C/(Q + OB - C)$	Maximise net benefits but unmeasurable	Serves no purpose

the indirect benefits. These would fall with the increasing age of beneficiaries and as the relative importance of the life years increased. Similarly, the magnitude of the error would fall if indirect benefits were measured by the value of future taxation and not the full value of production. While it would make no difference to the ranking of health projects if lives were converted into dollars or vice versa, it would appear preferable to convert dollars into life years especially when the indirect benefits were relatively

¹⁴ For the most marginal project let

$$(Q + OB)/C = \lambda$$

where λ is the "shadow price of capital" in this context.
From this:

$$Q = \lambda C + OB$$

The minimum value of life, Q , is obtained when $\lambda = 1$.

unimportant. This would discourage the inappropriate comparison of health related and financial projects.

5. Conclusions

The chief conclusion of this paper is that there are still significant unresolved issues in the theory and application of cost utility analysis. Most economists have uncritically assumed that the theoretical apparatus of conventional welfare theory is the appropriate gold standard in all decision contexts. It has been argued in this paper that this is not necessarily an appropriate assumption and that economic evaluation in the health sector has, in fact, been based upon a different value system. The question is not which is right and which is wrong; rather, it is an issue of which *do we wish* to have as the basis for our resource allocation. At present, QALYs or HYE_s imply utilitarian values to the extent that value - as reflected in the determination of equivalent health years - is defined by people's preferences. However as each person's HYE is given an equal vote in the allocation of resources, CUA is more accurately described as quasi - utilitarian.

The second issue of conceptual confusion discussed here has been the inclusion of indirect production benefits when the benefits of life are *separately* measured by HYE_s. The current convention in welfare economics and cost benefit analysis is to separate issues of production and distribution. It has been argued here that in the health sector this is not possible at least with respect to indirect benefits. The chief beneficiaries of increased output from a life extending project are the individuals whose lives have been separately included as a benefit. Double counting can only be avoided by netting out consumption from the value of production. However, even the remaining net benefits have very precise distributional consequences. The major beneficiaries are the heirs of the individual whose life is saved. For this reason it has been suggested that the rather vague concept of "social benefits" and "social costs" be replaced with an analysis which compares the costs to be borne by an identified group with the benefits to be gained by an identified group. The relevant policy decision is whether or not the former group will accept these costs in order to bestow the benefits on the latter group.

Even with a satisfactory resolution of these conceptual issues the present paper has documented a formidable list of unresolved questions. These are primarily associated with the measurement of utility. In a recent critique, Carr-Hill (1989) concludes by "doubting the utility of a global index given the wide variety of assumptions involved". The contrary view put forward by advocates of CUA is that the underlying assumptions

are implicit in any decisions that are made and that the major strength of CUA, as with CBA more generally, is that the assumptions are made explicit; that they may be located and subjected to sensitivity analysis.

The unresolved questions outlined in this paper should be kept in perspective. While their resolution will improve and refine the methodology and provide a more satisfactory theoretical basis for an evaluation, in many cases this is unlikely to result in a substantial, quantitative, difference to the measurement. The available studies show differences between the major quality of life techniques but a surprising similarity in the order of magnitude of the results. Other issues, such as the distribution of benefits and the choice of a discount rate are not unique to CUA or to the economic evaluation of health care. They are issues which must be faced in any evaluative methodology. Perhaps the most fundamental defence of CUA is that at present there is no alternative methodology which avoids the deficiencies of the willingness to pay approach to valuing human life but which simultaneously takes into account the strength of preferences for a health state. The cost utility ratio does not summarise all of the factors relevant to the assessment of health projects but it does embody a significantly important component of the relevant information and in a sufficiently comprehensible format that it should narrow the breadth of disagreement and limit the scope for arbitrary decision making.

References

- Abel-Smith, B. (1985), "Global perspective on health service financing", *Social Science and Medicine*, 21, 9, 957-963.
- Birch, S. and Donaldson, C. (1987), "Application of cost benefit analysis to health care: departures from welfare economic theory", *Journal of Health Economics*, 6, 3, 221-226.
- Boyd, N.F. et al (1982), "A comparison of methods of assessing value quality in laryngeal cancer", in Deber, R.B. and Thompson, (eds.) *Cancer in Health Care: Decision Making and Effectiveness*, Department of Health Administration, University of Toronto, 141-144.
- Broome, J. (1978), "Trying to value a life", *Journal of Public Economics*, 9, 91-100.
- Broome, J. (1979), "Trying to value a life: a reply", *Journal of Public Economics*, 12, 259-262.
- Brooks, R.G. (1988), *Scaling in health status measurement: outline guide and commentary*, Swedish Institute of Health Economics.
- Buchanan, J.M. and Faith, R. (1979), "Trying again to value a life", *Journal of Public Economics*, 12, 245-248.
- Buxton, M., Ashby, J. and O'Hanlon, M. (1986), *Valuation of health states using the time trade-off approach*, HERG Discussion Paper No. 2, Health Economics Research Group, Brunel University, Middlesex.
- Carr-Hill, R.A. (1989), "Assumptions of the QALY procedure", *Social Science and Medicine*, 29, 3, 469-477.
- Churchill et al (1984), "Cost effectiveness analysis comparing continuous ambulatory peritoneal dialysis to hospital haemodialysis", *Medical Decision Making*, 4, 20-23.
- Cooper, B. and Brody, W. (1976), *1972 lifetime earnings by age, sex, race and education level*, Research and Statistics Note No. 12, U.S. Department of Health, Education and Welfare, Washington.
- Cooper, B. and Rice, D. (1976), "The economic cost of illness revisited", *Social Security Bulletin*, 39, 2, 21-36.
- Dowie, J.A. (1970), "Valuing the benefits of health improvement", *Australian Economic Papers*, 9, 14, 21-41.
- Drummond, M. (1981), *Studies in Economic Appraisal in Health Care*, Oxford University Press, Oxford.
- Drummond, M. (1987), "Discussion: Torrance's approach to measuring health related quality of life", *Journal of Chronic Disease*, 40, 6, 601-603.

- Enthoven, A.C. (1988), "Managed competition: An agenda for action", *Health Affairs*, 7, 3, 25-47.
- Epstein, A.M., Hall, J.A. et al (1989), "Using proxies to evaluate quality of life", *Medical Care*, 27, 3, 91-98.
- Evans, R.W. et al (1985), "The quality of life of patients with end stage renal disease", *New England Journal of Medicine*, 312, 533-539.
- Evans, R.W. et al (1987), "The quality of life of kidney and heart transplant recipients", *Transplant Procedure*, 17, 1579-82.
- Evans, D.B. (1990), "The discount rate for use in public sector projects", in Scotton, R.B. and Goss, J., *Economic Evaluation of Health Services*, Australian Institute of Health, Canberra.
- Gafni, A. and Torrance, G.W. (1984), "Risk attitude and time preference in health", *Management Science*, 30, 4, 440-451.
- Gudex, C. (1986), *QALYS and their use by the health service*, Discussion Paper 20, Centre for Health Economics, University of York.
- Harris, J. (1987), "QALYfying the value of life", *Journal of Medical Ethics*, 13, 117-123.
- Hellinger, F.J. (1989), "Expected utility theory and risky choices with health outcomes", *Medical Care*, 27, 3, 273-279.
- Hershey, J.C., Kunreuther, J.C. and Schoemaker, P.J. (1982), "Sources of bias in assessment procedures for utility functions", *Management Science*, 29, 8, 936-954.
- Hershey, J.C. and Schoemaker, J.H. (1985), "Probability versus certainty equivalence methods in utility measurement: are they equivalent", *Management Science*, 31, 10, 12, 13-1229.
- Hodgson, T. and Meiners, M. (1979), *Guidelines for cost illness studies in the public health service*, Public Health Service Task Force on Cost of Illness Studies, Washington.
- Jones-Lee, M.J. (1979), "Trying to value a life", *Journal of Public Economics*, 12, 249-256.
- Kaplan, R.M., Bush, J. and Berry, C. (1976), "Health states: types of validity and the index of well being", *Health Services Research*, 11, 4, 478-507.
- Kaplan, R.M. and Bush, J.W. (1982), "Health related quality of life measurement for evaluation research and policy analysis", *Health Psychology*, 1, 61-8.
- Klarman, H.E. (1965), "Syphilis control programs", in Dorfman, R. (ed.), *Measuring benefits of government investments*, Brookings Institution, Washington D.C., 367-414.
- Kuhse, H. and Singer, P. (1988), "Age and the allocation of medical resources", *The Journal of Medicine and Philosophy*, 13, 101-116.

- Landefeld, S. and Seskin, E. (1982), "The economic value of life: linking theory to practice", *American Journal of Public Health*, 72, 6, 555-566.
- Linard, K. (1990), "Decision contexts and decision rules for economic evaluation of health services", in Scotton, R.B. and Goss, J., *Economic Evaluation of Health Services*, Australian Institute of Health, Canberra.
- Lipscomb, J. (1989), "Time preference for cost effectiveness analysis of medical care", *Inquiry* 27, 3, 233-253.
- Llewellyn-Thomas, H., Sutherland, H.J. et al (1984), "Describing health states: methodological issues in obtaining values for health states", *Medical Care*, 22, 6, 543-552.
- Loomes, G. and McKenzie, L. (1989), "The use of QALYS in health care decision making", *Social Science in Medicine*, 28, 4, 299-308.
- Mehrez, A. and Gafni, A. (1989a), "Quality adjusted life years, utility theory and healthy year equivalents", *Medical Decision Making*, 9, 2, 142-149.
- Mehrez, A. and Gafni, A. (1989b), *Evaluation health related quality of life: interpretation for the time trade off technique*, Working Paper, Centre for Health Economics and Policy Analysis, McMaster University.
- Mishan, E.J. (1971), "Evaluation of life and limb: a theoretical approach", *Journal of Political Economy*, 687-705.
- McDowell, I. and Newell, C. (1987), *Measuring health: a guide to rating scales and questionnaires*, Oxford University Press, New York.
- Mooney, G. and Olsen, J.A. (1989), *QALYS: where next?*, mimeo, Institute of Social Medicine, University of Copenhagen.
- Mushkin, S. (1962), "Health as an investment", *Journal of Political Economy*, 70, 5, 129-157.
- Read, J.L., Quinn, R.J., Berwick, D.M., Fineberg, H.V. and Weinstein, M.C. (1984), "Preferences for health outcomes: comparison of assessment methods", *Medical Decision Making*, 4, 3, 315-329.
- Rice, D. and Cooper, B. (1967), "The economic value of human life", *American Journal of Public Health*, 57, 11, 1954-1966.
- Richardson, J. (1990), "Cost utility analysis: what should be measured - utility, value or healthy year equivalents", paper presented to the Second World Congress on Health Economics, University of Zurich, Switzerland, September 10-14, 1990.

- Richardson, J., Hall, J. and Salkeld, G. (1990), "Cost utility analysis: the compatibility of measurement techniques in the measurement of utility through time" in Selby Smith, C. (ed.), *Economics and Health 1989*, PSMI, Monash University, 31-60.
- Robinson, J.C. (1986), "Philisophical origins of the economic valuation of life", *The Millbank Quarterly*, 64, 1, 133-155.
- Rosser, R. and Kind, P. (1978), "A scale of valuations of states of illness: is there a social consensus?", *International Journal of Epidemiology*, 7, 4, 347-358.
- Sackett, D.L. and Torrance, G.W. (1978), "The utility of different health states as perceived by the general public", *Journal of Chronic Diseases*, 31, 697-704.
- Schieber, G.J. and Poullier, J.P. (1989), "International health care expenditure trends: 1987", *Health Affairs*, 8, 3, 169-177.
- Schoemaker, P. (1982), "The Expected Utility Model: its variants, purposes, evidence and limitations", *Journal of Economic Literature*, 20, 529-563.
- Scotton, R.B. (1990), "Integrating Medicare with private health insurance: the best of both worlds", in Selby Smith, C. (ed.), *Economics and Health 1989*, Proceedings of the Eleventh Australian Conference of Health Economists, PSMI, Monash, 219-238.
- Sutherland, H.J., Dunn, V. and Boyd, N.F. (1983), "Measurement of values for states of health with linear analog scales", *Medical Decision Making*, 3, 4, 477-487.
- Torrance, G.W. (1976), "Social preferences for health states: an empirical evaluation of three measurement techniques:", *Socio-Economic Planning Sciences*, 10, 3, 129-136.
- Torrance, G.W. (1982), "Multiattribute utility theory as a method of measuring preferences for health", in Kane, R. and Kane R. (eds.), *Values and long term care*, Lexington.
- Torrance, G.W. (1986), "Measurement of health-state utilities for economic appraisal: a review", *Journal of Health Economics*, 5, 1-30.
- Torrance, G.W. (1987), "Utility approach to measuring health-related quality of life", *Journal of Chronic Diseases*, 40, 6, 593-600.
- Torrance, G.W. and Feeny, D. (1989), "Utilities and Quality Adjusted Life Years", *International Journal of Technology Assessment in Health Care* (forthcoming).
- Warner, K.E. and Luce, B.R. (1982), *Cost benefit and cost effectiveness analysis in health care: Principles, practice and potential*, Health Administration Press, Ann Arbor, Michigan.
- Weinstein, M.C. and Stason, W.B. (1976), *Hypertension: A Policy Perspective*, Harvard University Press, (Mass.), Cambridge.
- Williams, A. (1979), A note on "Trying to value a life", *Journal of Public Economics*, 12, 257-258.

- Williams, A. (1985), "Economics of coronary artery bypass grafting", *British Medical Journal*, 291, 326-329.
- Williams, A. (1987), "Response: QALYfying the value of life", *Journal of Medical Ethics*, 13, 123.
- Wilson, D.K., Kaplan, R.M. and Schneiderman, L.J. (1987), "Framing of decisions and selections of alternatives in health care", *Social Behaviour*, 2, 57-59.
- Wright, S.J. (1986), *Age sex and health: a summary of findings from the York health evaluation survey*, Discussion Paper 15, Centre for Health Economics, University of York.